{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:16:31Z","timestamp":1730434591734,"version":"3.28.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,31]]},"DOI":"10.7759\/cureus.72774","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:39:50Z","timestamp":1730392790000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Novel Versus Traditional Antiemetic Agents in Preventing Chemotherapy-Induced Nausea and Vomiting With Moderate or Highly Emetogenic Chemotherapy: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Sally M","family":"Nashed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami Kamal A","family":"Morcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Atif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Shehryar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safiyyah M","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Roshan","family":"Zeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talha A","family":"Zia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Jameel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Nausea and Vomiting Related to Cancer Treatment (PDQ\u00ae)-Health Professional Version. (2023). Accessed. September 1, 2024: https:\/\/www.cancer.gov\/about-cancer\/treatment\/side-effects\/nausea\/nausea-hp-pdq."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00400","article-title":"Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective","volume":"10","author":"Vaid AK","year":"2020","unstructured":"Vaid AK, Gupta S, Doval DC, et al.. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol. 2020, 10:400. 10.3389\/fonc.2020.00400","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/595894","article-title":"Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting","volume":"2015","author":"Navari RM","year":"2015","unstructured":"Navari RM. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int. 2015, 2015:595894. 10.1155\/2015\/595894","journal-title":"Biomed Res Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.166181","article-title":"The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo","volume":"335","author":"Rojas C","year":"2010","unstructured":"Rojas C, Li Y, Zhang J, et al.. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010, 335:362-368. 10.1124\/jpet.110.166181","journal-title":"J Pharmacol Exp Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3123","article-title":"Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study","volume":"9","author":"Chang J","year":"2020","unstructured":"Chang J, Chen G, Wang D, et al.. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. Cancer Med. 2020, 9:5134-5142. 10.1002\/cam4.3123","journal-title":"Cancer Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.359","article-title":"Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial","volume":"38","author":"Sun S","year":"2023","unstructured":"Sun S, Ko YH, Jin JY, et al.. Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial. Korean J Intern Med. 2023, 38:406-416. 10.3904\/kjim.2020.359","journal-title":"Korean J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012775.pub2","article-title":"Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis","volume":"11","author":"Piechotta V","year":"2021","unstructured":"Piechotta V, Adams A, Haque M, et al.. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev. 2021, 11:CD012775. 10.1002\/14651858.CD012775.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102512","article-title":"Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis","volume":"115","author":"Filetti M","year":"2023","unstructured":"Filetti M, Lombardi P, Giusti R, et al.. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Cancer Treat Rev. 2023, 115:102512. 10.1016\/j.ctrv.2023.102512","journal-title":"Cancer Treat Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13888","article-title":"A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"26","author":"Zelek L","year":"2021","unstructured":"Zelek L, Debourdeau P, Bourgeois H, et al.. A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Oncologist. 2021, 26:e1870-e1879. 10.1002\/onco.13888","journal-title":"Oncologist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041737","article-title":"Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy","volume":"10","author":"Minatogawa H","year":"2020","unstructured":"Minatogawa H, Izawa N, Kawaguchi T, et al.. Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy. BMJ Open. 2020, 10:e041737. 10.1136\/bmjopen-2020-041737","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4237-7","article-title":"Should palonosetron be a preferred 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis","volume":"26","author":"Chow R","year":"2018","unstructured":"Chow R, Warr DG, Navari RM, et al.. Should palonosetron be a preferred 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018, 26:2519-2549. 10.1007\/s00520-018-4237-7","journal-title":"Support Care Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000593","article-title":"A randomized controlled pilot study comparing the impact of aprepitant and fosaprepitant on chemotherapy induced nausea and vomiting in patients treated for gynecologic cancer","volume":"26","author":"Micha JP","year":"2016","unstructured":"Micha JP, Rettenmaier MA, Brown JV 3rd, Mendivil A, Abaid LN, Lopez KL, Goldstein BH. A randomized controlled pilot study comparing the impact of aprepitant and fosaprepitant on chemotherapy induced nausea and vomiting in patients treated for gynecologic cancer. Int J Gynecol Cancer. 2016, 26:389-393. 10.1097\/IGC.0000000000000593","journal-title":"Int J Gynecol Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2865-8","article-title":"Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study","volume":"24","author":"Seol YM","year":"2016","unstructured":"Seol YM, Kim HJ, Choi YJ, et al.. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer. 2016, 24:945-952. 10.1007\/s00520-015-2865-8","journal-title":"Support Care Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0680-9","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study","volume":"18","author":"Rapoport BL","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA, et al.. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010, 18:423-431. 10.1007\/s00520-009-0680-9","journal-title":"Support Care Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-9957-9","article-title":"A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy","volume":"113","author":"Yeo W","year":"2009","unstructured":"Yeo W, Mo FK, Suen JJ, et al.. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009, 113:529-535. 10.1007\/s10549-008-9957-9","journal-title":"Breast Cancer Res Treat"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0990-y","article-title":"Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study","volume":"19","author":"Boccia RV","year":"2011","unstructured":"Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011, 19:1609-1617. 10.1007\/s00520-010-0990-y","journal-title":"Support Care Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment","volume":"17","author":"Schmoll HJ","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli-Bigelli S, et al.. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006, 17:1000-1006. 10.1093\/annonc\/mdl019","journal-title":"Ann Oncol"},{"key":"ref19","article-title":"Olanzapine","author":"Thomas K","year":"2024","unstructured":"Thomas K, Saadabadi A. Olanzapine. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2015.002477","article-title":"Cheaper options in the prevention of chemotherapy-induced nausea and vomiting","volume":"2","author":"Gyawali B","year":"2016","unstructured":"Gyawali B, Poudyal BS, Iddawela M. Cheaper options in the prevention of chemotherapy-induced nausea and vomiting. J Glob Oncol. 2016, 2:145-153. 10.1200\/JGO.2015.002477","journal-title":"J Glob Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.05.003","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study","volume":"47","author":"Mizukami N","year":"2014","unstructured":"Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, Yamakage M. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2014, 47:542-550. 10.1016\/j.jpainsymman.2013.05.003","journal-title":"J Pain Symptom Manage"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6121","article-title":"Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"12","author":"Zelek L","year":"2023","unstructured":"Zelek L, Navari R, Aapro M, Scott\u00e9 F. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023, 12:15769-15776. 10.1002\/cam4.6121","journal-title":"Cancer Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-00909-6","article-title":"Enhancement strategies for transdermal drug delivery systems: current trends and applications","volume":"12","author":"Ramadon D","year":"2022","unstructured":"Ramadon D, McCrudden MT, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug Deliv Transl Res. 2022, 12:758-791. 10.1007\/s13346-021-00909-6","journal-title":"Drug Deliv Transl Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-016-0110-2","article-title":"Newest drugs for chronic unexplained nausea and vomiting","volume":"14","author":"Hasler WL","year":"2016","unstructured":"Hasler WL. Newest drugs for chronic unexplained nausea and vomiting\r\n. Curr Treat Options Gastroenterol. 2016, 14:371-385. 10.1007\/s11938-016-0110-2","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01818-3","article-title":"Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis","volume":"26","author":"Aogi K","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T, et al.. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2021, 26:1-17. 10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/299355-comparative-efficacy-of-novel-versus-traditional-antiemetic-agents-in-preventing-chemotherapy-induced-nausea-and-vomiting-with-moderate-or-highly-emetogenic-chemotherapy-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:39:53Z","timestamp":1730392793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/299355-comparative-efficacy-of-novel-versus-traditional-antiemetic-agents-in-preventing-chemotherapy-induced-nausea-and-vomiting-with-moderate-or-highly-emetogenic-chemotherapy-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.72774","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}